2026 Global: Minimally Invasive Weight Loss (Bariatric) Devices Market -Competitive Review (2032) report
Description
The 2026 Global: Minimally Invasive Weight Loss (Bariatric) Devices Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Aggressive growth in the Minimally Invasive Weight Loss Devices market is led by a core group of global medical technology companies that push innovation across intragastric balloons, endoscopic suturing systems, and adjunct devices. Apollo Endosurgery, headquartered in Austin, United States, is a pioneer in endoscopic bariatric techniques and markets the Orbera and ESG platforms. Allurion Technologies, based in Waltham, United States, is known for the Elipse gastric balloon and its family of non-surgical weight loss solutions. Obalon Therapeutics, headquartered in Carlsbad, United States, offers a gas-filled balloon system designed for repeat placement during treatment. Medtronic plc, domiciled in Dublin, Ireland, contributes to device development spanning digestion-related therapies and endoscopic tools. Boston Scientific Corporation, headquartered in Marlborough, United States, supplies endoscopic devices and access systems used in bariatric procedures. Together these companies shape treatment options for patients seeking non-surgical and minimally invasive weight management. Strategic partnerships and acquisitions amplify their reach.
Ongoing device innovation in endoscopy and imaging complements balloon-based therapies as major players expand capabilities in the bariatric continuum. Olympus Corporation, headquartered in Tokyo, Japan, provides advanced endoscopic platforms and accessories that support ESG, plication, and diagnosis across global markets. Johnson & Johnson, with its Ethicon division, based in New Brunswick, United States, leverages suturing and energy devices to enable precise tissue manipulation during minimally invasive weight loss procedures. Stryker Corporation, anchored in Kalamazoo, United States, offers endoscopic stapling and access products that underlie surgical and endoscopic bariatric interventions. ConMed Corporation, headquartered in Utica, United States, supplies flexible instrumentation and hemostasis devices used in endoscopic weight loss therapies. Terumo Corporation, located in Tokyo, Japan, contributes catheter-based systems and disposables that support intragastric balloons deployment and endoluminal procedures. These players together broaden procedural options and drive standardization, safety, and training across diverse healthcare settings worldwide. Fostering collaboration across disciplines accelerates adoption.
Together, these ten companies form a diversified ecosystem that supports the full spectrum of minimally invasive weight loss therapies, from non-surgical balloons to endoscopic suturing and adjunct tools. Their global footprints enable rapid dissemination of clinical evidence, training programs, and FDA and CE approvals that expand patient access. Market leadership increasingly depends on safety profiles, device durability, ease of use, and the ability to tailor therapy to individual anatomy and preferences. As demand for non-surgical options grows, collaborations between balloon manufacturers, endoscopic innovators, and surgical device companies drive integrated care pathways that combine lifestyle modification, endoscopy, and timed follow-ups. This convergence is reshaping payer strategies and reimbursement models by emphasizing outcomes, reversibility, and patient satisfaction. Looking ahead, sustained investment in R&D—especially in imaging, deployment simplicity, and real-time analytics—will define competitive advantage and sustain growth across North America, Europe, and Asia-Pacific markets. Regulatory harmonization and cross-border training will accelerate adoption worldwide.
Aggressive growth in the Minimally Invasive Weight Loss Devices market is led by a core group of global medical technology companies that push innovation across intragastric balloons, endoscopic suturing systems, and adjunct devices. Apollo Endosurgery, headquartered in Austin, United States, is a pioneer in endoscopic bariatric techniques and markets the Orbera and ESG platforms. Allurion Technologies, based in Waltham, United States, is known for the Elipse gastric balloon and its family of non-surgical weight loss solutions. Obalon Therapeutics, headquartered in Carlsbad, United States, offers a gas-filled balloon system designed for repeat placement during treatment. Medtronic plc, domiciled in Dublin, Ireland, contributes to device development spanning digestion-related therapies and endoscopic tools. Boston Scientific Corporation, headquartered in Marlborough, United States, supplies endoscopic devices and access systems used in bariatric procedures. Together these companies shape treatment options for patients seeking non-surgical and minimally invasive weight management. Strategic partnerships and acquisitions amplify their reach.
Ongoing device innovation in endoscopy and imaging complements balloon-based therapies as major players expand capabilities in the bariatric continuum. Olympus Corporation, headquartered in Tokyo, Japan, provides advanced endoscopic platforms and accessories that support ESG, plication, and diagnosis across global markets. Johnson & Johnson, with its Ethicon division, based in New Brunswick, United States, leverages suturing and energy devices to enable precise tissue manipulation during minimally invasive weight loss procedures. Stryker Corporation, anchored in Kalamazoo, United States, offers endoscopic stapling and access products that underlie surgical and endoscopic bariatric interventions. ConMed Corporation, headquartered in Utica, United States, supplies flexible instrumentation and hemostasis devices used in endoscopic weight loss therapies. Terumo Corporation, located in Tokyo, Japan, contributes catheter-based systems and disposables that support intragastric balloons deployment and endoluminal procedures. These players together broaden procedural options and drive standardization, safety, and training across diverse healthcare settings worldwide. Fostering collaboration across disciplines accelerates adoption.
Together, these ten companies form a diversified ecosystem that supports the full spectrum of minimally invasive weight loss therapies, from non-surgical balloons to endoscopic suturing and adjunct tools. Their global footprints enable rapid dissemination of clinical evidence, training programs, and FDA and CE approvals that expand patient access. Market leadership increasingly depends on safety profiles, device durability, ease of use, and the ability to tailor therapy to individual anatomy and preferences. As demand for non-surgical options grows, collaborations between balloon manufacturers, endoscopic innovators, and surgical device companies drive integrated care pathways that combine lifestyle modification, endoscopy, and timed follow-ups. This convergence is reshaping payer strategies and reimbursement models by emphasizing outcomes, reversibility, and patient satisfaction. Looking ahead, sustained investment in R&D—especially in imaging, deployment simplicity, and real-time analytics—will define competitive advantage and sustain growth across North America, Europe, and Asia-Pacific markets. Regulatory harmonization and cross-border training will accelerate adoption worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
